Qinyang People's Hospital
Jiaozuo, Henan, China
NCT Number: NCT02322944
This study aims to develop quality improvement strategies and relevant tools focusing on reperfusion therapy in patients with STEMI, and to evaluate their effectiveness via a hospital-level cluster randomized clinical trial, based on the nationally representative collaborative network of over 100 hospitals established in China PEACE retrospective study. In a baseline survey period, through consecutively recruiting all eligible inpatients and collecting relevant medical information, the performance of all participating hospitals before the implementation of the intervention will be assessed. During the following intervention period, 6-10 hospitals that show the strong willingness and ability to collaborate will be selected as "process optimization group". Their clinical pathways and team building will be re-organized for the purpose of quality improvement, and develop individualized treatment strategies and process. Meanwhile, other participating hospitals will be divided into intervention and control groups in a 1:1 ratio, in which the intervention group will take the treatment improvement strategy into implementation, while the control group will maintain the routine practice pattern. All hospitals will consecutively recruit qualified patients in the same method adopted in baseline period. Then the reperfusion rates and other performance measures will be compared among different groups (process optimization, intervention and control).
Looking for future studies?
Notify MeAll sexes
Interventional
Not applicable
Jiaozuo, Henan, China
This study aims to develop quality improvement strategies and relevant tools focusing on reperfusion therapy in patients with STEMI, and to evaluate their effectiveness via a hospital-level cluster randomized clinical trial, based on the nationally representative collaborative network of over 100 hospitals established in China PEACE retrospective study. The primary outcome measure is reperfusion rate among eligible patients with STEMI, and secondary ones include timeliness of primary PCI (D2B) and fibrinolytic therapy (D2N). the assessment is based on consecutively recruiting all eligible inpatients, as well as collecting relevant medical information via a case report form finished by local doctors and central medical record abstraction.
During the first study period, the baseline performance of all 100 participating hospitals before the implementation of the intervention will be assessed.
During the following period, 3-5 PCI-capable and 3-5 non-PCI capable hospitals that show the strong willingness and ability to collaborate will be selected as "process optimization group". Their clinical pathways and team building will be re-organized for the purpose of quality improvement, and develop individualized treatment strategies and process, including examining local hospitals' workflow to determine the key link affecting the rate of reperfusion therapy and its timeliness (such as pre-paid policy for fibrinolytic or PPCI, thrombolytic drug preparation, cardiac catheterization laboratory preparation, transferring from the ER to the Cath lab, interventional medical team gathering, etc.). Also, QI strategies and tools developed in the current study will be provided to these hospital, including training in standardized treatment pattern; building quality management team and determining improvement goals; periodical quality feedback report and regular quality meeting; tools like a wristband in order to remind all medical staff involved in the treatment process, workflow posters and cards, a CRF including a flowchart to inform the management steps, study website serving as the communication platform.
Meanwhile, other participating hospitals will be divided into intervention and control groups in a 1:1 ratio using minimization allocation, in which the intervention group will take the QI strategies and tools developed in the current study as mentioned above, while the control group will maintain the routine practice pattern. Then the outcome measures and other performance indicators will be compared among different groups (process optimization, intervention and control).
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Training in standardized treatment pattern; building quality management team and determining improvement goals; tools (a wristband in order to remind all medical staff involved in the treatment process; workflow posters and cards; a CRF including a flowchart to inform the management steps); periodical quality feedback report and regular quality meeting; study website serving as the communication platform.
Examining local hospitals' workflow to determine the key link affecting the rate of reperfusion therapy and its timeliness (such as thrombolytic drug preparation, cardiac catheterization laboratory preparation, transferring from the ER to the cath lab, interventional medical team gathering, etc.) and systems (such as pre-paid policy for thrombolysis or PPCI)
Time frame: 24 hours after admission
Reperfusion therapy rate is defined as utilization rate of thrombolytic therapy or primary PCI treatment among patients indicated with the reperfusion therapy.
Time frame: 24 hours after admission
The proportion of door to balloon (D2B) within 90 minutes among all patients receiving PPCI.
Time frame: 24 hours after admission
The proportion of door to needle time (D2N) within 30 minutes among all patients receiving fibrinolytic therapy.
Time frame: 24 hours after admission
Door to balloon (D2B) time
Time frame: 24 hours after admission
Door to needle (D2N) time
Time frame: 10 days on average (during hospitalization)
Proportion of in-hospital mortality or withdraw treatment due to a terminal status at discharge.
Time frame: 24 hours after admission
Proportion of aspirin use within 24 hours of admission among eligible patients
Time frame: 24 hours after admission
Proportion of heparin use within 24 hours of admission among eligible patients
Time frame: 24 hours after admission
Proportion of left ventricular function evaluation within 24 hours of admission among all patients.
Time frame: 10 days on average (during hospitalization)
Proportion of β-blockers use during hospitalization among eligible patients.
Time frame: 10 days on average (during hospitalization)
Proportion of statins use during hospitalization among eligible patients.
Time frame: 10 days on average (during hospitalization)
Proportion of ACEI/ARB use during hospitalization among eligible patients.
Time frame: 10 days on average (during hospitalization)
Proportion of aspirin use at discharge among eligible patients.
Time frame: 10 days on average (during hospitalization)
Proportion of Clopidogrel (or ticagrelor) use at discharge among eligible patients.
Time frame: 10 days on average (during hospitalization)
Proportion of β-blockers use at discharge among eligible patients.
Time frame: 10 days on average (during hospitalization)
Proportion of ACEI/ARB use at discharge among eligible patients.
Time frame: 10 days on average (during hospitalization)
Proportion of statins use at discharge among eligible patients.
China National Center for Cardiovascular Diseases
Other Gov
China Patient-centered Evaluative Assessment of Cardiac Events II: Quality Improvement for Acute Myocardial Infarction
Acronym: PEACE-QI-AMI
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05853042
Acute Coronary Syndrome, Acute Myocardial Infarction
Minneapolis, Minnesota, United States
View Trial DetailsNCT06457815
Acute Myocardial Infarction
Middlesbrough, Teesside, United Kingdom
View Trial DetailsNCT04938661
Acute Coronary Syndrome, Acute Myocardial Infarction
Minneapolis, Minnesota, United States
View Trial DetailsNCT05149560
Acute Myocardial Infarction
Gothenburg, Sweden
View Trial Details